Arrowhead Pharmaceuticals Reports the P-III (PALISADE) Trial Results of Plozasiran to Treat Familial Chylomicronemia Syndrome (FCS)
Shots:
- The P-III (PALISADE) trial assessed plozasiran (25mg & 50mg, SC, Q3M) vs PBO to treat genetically confirmed/clinically diagnosed FCS in adults (n=75). Patients could join a 2-part extension period where all receive plozasiran post completing randomization
- Study showed a median reduction of -80% & -78% vs -17% in the fasting TG level with a median reduction of -93% & -96% vs -1% in APOC3 after 10mos. and reduced risk of developing acute pancreatitis by 83%
- The data was published in the NEJM & highlighted at ESC 2024 under the title, “A Randomised, Placebo-Controlled Phase 3 Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome”; will form the basis of NDA filing across the US in Q4’24 and other regions
Ref: Arrowhead | Image: Arrowhead
Related News:- Arrowhead Published New Findings from 2 P-II (SHASTA-2 & MUIR) studies for Plozasiran at AHA 2023
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
